Skye Bioscience ($SKYE) Misleading Clinical Expectations and Trial Outcome Case

S.D. California

Court

3:25-cv-03177

Case number

11/04/2024

Class period Start

10/03/2025

Class period End

01/16/2026

Lead Plaintiff motion deadline

$SKYE investors filed a claim against Skye Bioscience for allegedly overstating the efficacy and commercial potential of its obesity drug candidate nimacimab, and for failing to disclose known risks related to dosing and trial outcomes.
After the company reported topline Phase 2a results showing that nimacimab failed to meet its primary endpoint, $SKYE fell 60% on October 7, 2025.
$SKYE investors can join this case to be notified about potential recovery.
Case Details:

Skye Bioscience is a clinical-stage biopharmaceutical company developing therapies for metabolic disorders. Its lead product candidate, nimacimab, is a CB1 receptor-targeting antibody designed to treat obesity without central nervous system side effects. On August 15, 2024, Skye launched its 26-week Phase 2a trial, known as “CBeyond,” to evaluate the drug’s safety and efficacy in overweight or obese patients.

Throughout late 2024 and into 2025, Skye issued public updates highlighting the potential of nimacimab based on preclinical data. Executives cited weight-loss effects observed in animal studies and emphasized the drug’s novel mechanism of action, describing it as a differentiated treatment with significant commercial potential. The company also suggested that nimacimab could work in combination with existing GLP-1-based therapies.

On October 6, 2025, Skye reported topline Phase 2a results, revealing that the nimacimab monotherapy arm failed to meet its primary endpoint of achieving statistically significant weight loss compared to placebo. The company also disclosed lower-than-expected drug exposure, which raised questions about dosing adequacy. On the following day, October 7, 2025, $SKYE stock dropped 60%, reflecting investor reaction to the trial outcome.

Based on these events, $SKYE investors filed a claim against Skye Bioscience, alleging the company:
It overstated the clinical and commercial prospects of nimacimab.
It failed to disclose known limitations in dosing and trial design.
It misled investors about the likelihood of achieving positive Phase 2a results.
Investors argue that Skye Bioscience presented an overly optimistic view of its lead drug candidate, which led to losses when the trial results failed to meet expectations.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Appointment

Alleged Offence

Misleading Statements,

Financial Misrepresentation,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

10/06/2025

Filing date

11/17/2025

Lead Plaintiff Deadline

01/16/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.